We accelerate patient care by applying our experience, creative thinking and the latest innovations in health care to our drug development process.
There have been great strides made recently in treating the most difficult and debilitating health conditions people face. Yet, there is still much work to be done if we are going to find truly effective therapies for these conditions. At Pfizer, we work to make our drug development process more efficient by collaborating with unique partners and exploring new pathways that harness technology and emerging science. At the core of this work is the belief that collaboration – across organizations, industries and even therapeutic areas – is essential to driving measurable progress and revolutionizing care.
Leading a Transformative Approach to Precision Medicine
Working with IBM Health Watson fuels our immuno-oncology research
One of the major recent advances in the battle against cancer has been immuno-oncology, which uses the body’s immune system to fight the disease. The future of immuno-oncology may lie in combining therapies and tailoring them to unique tumor characteristics. Yet, the number of potential therapy combinations is almost impossible to quantify, let alone test. Therefore, one of the great challenges in immuno-oncology is to find ways to narrow the field of focus so we can more efficiently identify effective combinations.
To accelerate our work in this space, Pfizer is working with IBM Health Watson.